Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Barakaldo – page 12

205 clinical trials in Barakaldo, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Barakaldo at a glance
205
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

205 trials in Barakaldo

Open in trial search

Thrombotic thrombocytopenic purpura

Not recruiting

Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apadamtase Alfa
  • Sponsor:Baxalta Innovations GmbH

Parkinson's disease

Not recruiting

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis relapse

Not recruiting

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Squamous cell carcinoma of head and neck

Not recruiting

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study on the Safety of TAK-755, Rituximab, and Glucocorticoids for Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Apadamtase Alfa
  • Sponsor:Takeda Development Center Americas Inc.

Multiple system atrophy

Not recruiting

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Takeda Development Center Americas Inc.

Progressive supranuclear palsy

Not recruiting

Study of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt
  • Sponsor:Ferrer Internacional S.A.

Metachromatic leukodystrophy

Not recruiting

Study of Intrathecal Cebsulfase Alfa for Children with Late Infantile Metachromatic Leukodystrophy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Pancreatitis acute+1

Not recruiting

Study on Simvastatin for Preventing Recurrent Pancreatitis in Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lactose Monohydrate
  • Sponsor:Hospital General Universitario Dr. Balmis

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Hodgkin's disease

Not recruiting

Title: Comparing Brentuximab Vedotin plus ESHAP versus ESHAP alone in treating patients with relapsed or refractory classical Hodgkin's Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Fundacion Geltamo

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Barakaldo

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on acute cerebral ischemic stroke treatments and groundbreaking studies in Parkinson's disease management, including trials of novel compounds like NEU-411 and CVN424.

  • Stroke intervention studies
  • Early Parkinson's treatments
  • Neurological therapeutics

These trials aim to improve patient outcomes and develop more effective treatment strategies.

02 Oncology Research

Comprehensive cancer studies including treatments for metastatic prostate cancer, pancreatic adenocarcinoma, and innovative approaches in breast cancer therapy.

  • Prostate cancer treatments
  • Hepatic tumors
  • Breast cancer therapies

Focus on developing targeted therapies and improving survival rates across various cancer types.

03 Infectious Diseases

Studies addressing COVID-19 vaccination strategies and treatments for invasive candidiasis, with particular attention to antimicrobial therapies.

  • COVID-19 boosters
  • Fungal infections
  • Endocarditis treatments

These trials evaluate new therapeutic approaches and vaccine effectiveness.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.